v3.25.2
Supplemental Balance Sheet Information
 9 Months Ended
Jun. 30, 2025
Supplemental Balance Sheet Information [Abstract]  
Supplemental Balance Sheet Information

NOTE 5 – Supplemental Balance Sheet Information

 

Inventory

 

Inventory consisted of the following: 

 

   As of
June 30,
2025		   As of
September 30,
2024		 
Component inventory  $793,383   $877,065 
Work-in-process   328,368    192,360 
Finished goods   775,950    1,565,728 
Total  $1,897,701   $2,635,153 

 

Excess and obsolete valuation reserve adjustments reflected as a reduction of work-in-process inventory at June 30, 2025 and September 30, 2024 were $7,500 and zero, respectively.

 

Intangibles

 

Intangible assets rollforward is as follows: 

 

   Useful Life    
Net Intangibles, September 30, 2024  12-13 years  $67,262 
Less: amortization      (16,737)
Net Intangibles, June 30, 2025     $50,525 

 

Amortization expense was $5,579 and $16,737 for the three and nine months ended June 30, 2025, respectively, and $5,578 and $16,736 for the three and nine months ended June 30, 2024, respectively.

 

Property and Equipment, Net

 

Property and equipment held for use by category are presented in the following table:  

 

   As of
June 30,
2025		   As of
September 30,
2024		 
Equipment and furniture  $1,054,666   $976,303 
Total property and equipment   1,054,666    976,303 
Less accumulated depreciation   (740,078)   (559,460)
Property and equipment, net  $314,588   $   416,843 

NeuroOne Medical Technologies Corporation

Notes to Condensed Financial Statements

(unaudited)

 

Depreciation expense was $61,015 and $180,618 for the three months and nine months ended June 30, 2025, respectively, and $57,529 and $165,928 for the three and nine months ended June 30, 2024, respectively.